Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

HLS Therapeutics Inc T.HLS

Alternate Symbol(s):  HLTRF

HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. The Vascepa (icosapent ethyl capsules) is a single-molecule prescription product in use to reduce the risk of cardiovascular events.


TSX:HLS - Post by User

Bullboard Posts
Post by Pat123on Feb 26, 2018 11:13pm
95 Views
Post# 27625717

I'm voting NO

I'm voting NO

Why I'm voting to reject the proposition:

 

1) AM shareholders are not getting much measurable value for the immediate cash infusion to HLS balance sheet and their fast track listing on a stock exchange.
  • HLS will receive $25M from AM balance sheet
  • Post arrangement, the Automodular value based on circular pro forma market cap of the new entity will be $24.64M (New entity value (p.24): $314,113M X 7.92% (Future Automodular ownership of the new entity - 2,151,900 / 27,429,897)
  • Net ~0

2) AM shareholders didn't invest in the company to see their initial AM investment now tied to a volatile Bio company and see their capital at risk.  AM was a deep value stock with tons of cash to support it's value. HLS could have good growth potential but that's not the point. 

3) The amount reserved in the Preferred structure (after the GM litigation payment) could be accesible in 2 years only.

4) Current HLS shareholders could increase the new entity share float by almost 4.9M shares if they exercise all their options after the lock-Up agreement (180 days after the effective date). The number of outstanding shares could increase from 27.430M to 32.329M. Consequently, current AM shareholder would see their ownership shrink from 7.92% to 6.66%. Their exercise price is $9.5-$10

5) I always found that AM management made good decisions to optimize shareholder value over the 6-7 years that I've owned the stock. But this time, they are not able to demonstrate much added value to AM shareholders. Also, I have a hard understanding why they didn't wait until the trial date before sending the circular. The timing looks really bad.

Please, just close down the company and redistribute the net cash. That's what most shareholders were expecting.

If I'm missing something, please don't hesitate. For all the reasons above, for me the decision is simple: Reject the proposition.

This is my opinion

Good luck

 


Bullboard Posts